C4d-negative antibody-mediated rejection with high anti-angiotensin II type i receptor antibodies in absence of donor-specific antibodies

Nephrology

Volumn 20, Issue 7, 2015, Pages 467-473

  Fuss, Alexander ^a,b   Hope, Christopher M ^a,b   Deayton, Susan ^c   Bennett, Greg Donald ^c   Holdsworth, Rhonda ^c   Carroll, Robert P ^a,b   Coates, P Toby H ^a,b  

^a Central and Northern Adelaide Renal and Transplantation Service   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

Author keywords

angiotensin II type 1 receptor; angiotensin receptor blocker; antibody; antibody mediated rejection; AT1R; atypical HLA antibody

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 TYPE 1 RECEPTOR ANTIBODY; COMPLEMENT COMPONENT C4D; HLA ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR; ANTIBODY; CD4 ANTIGEN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY MEDIATED REJECTION; ANTIBODY SPECIFICITY; CLINICAL ARTICLE; CONFERENCE PAPER; DISEASE SEVERITY; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MALIGNANT HYPERTENSION; MIDDLE AGED; PLASMAPHERESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; BLOOD; DONOR; GRAFT REJECTION; IMMUNOLOGY; PROSPECTIVE STUDY;

ADULT; AGED; ANTIBODIES; ANTIGENS, CD4; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RETROSPECTIVE STUDIES; TISSUE DONORS;

EID: 84930711696     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12441     Document Type: Conference Paper

References (23)

1. Amico P, Hönger G, Bielmann D, et al. Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigen-antibodies. Transplantation 2008; 85: 1557-1563.
2. Dragun D, Müller DN, Bräsen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N. Engl. J. Med. 2005; 352: 558-569.
3. Weidanz JA, Jacobson LM, Muehrer RJ, et al. ATR blockade reduces IFN-gamma production in lymphocytes in vivo and in vitro. Kidney Int. 2005; 67: 2134-2142.
4. Günther J, Kill A, Becker MO, et al. Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res. Ther. 2014; 16: R65.
5. Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J. Clin. Invest. 1999; 103: 945-952.
6. Siddiqui AH, Irani RA, Blackwell SC, Ramin SM, Kellems RE, Xia Y,. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: Correlation with disease severity. Hypertension 2010; 55: 386-393.
7. Fu ML, Herlitz H, Schulze W, et al. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J. Hypertens. 2000; 18: 945-953.
8. Becker MO, Kill A, Kutsche M, et al. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am. J. Respir. Crit. Care Med. 2014; 190: 808-817.
9. Dragun D, Bräsen JH, Schönemann C, et al. Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptor. Transplant. Proc. 2003; 35: 2104-2105.
10. Giral M, Foucher Y, Dufay A, et al. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am. J. Transplant. 2013; 13: 2567-2576.
11. Banasik M, Boratyńska M, Kos̈cielska-Kasprzak K, et al. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes. Transpl. Int. 2014; 27: 1029-1038.
12. Taniguchi M, Rebellato LM, Cai J, et al. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am. J. Transplant. 2013; 13: 2577-2589.
13. Hiemann NE, Meyer R, Wellnhofer E, et al. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation 2012; 94: 919-924.
14. Colvin RB,. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J. Am. Soc. Nephrol. 2007; 18: 1046-1056.
15. Unal H, Jagannathan R, Bhat MB, Karnik SS,. Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor. J. Biol. Chem. 2010; 285: 16341-16350.
16. Dragun D,. Agonistic antibody-triggered stimulation of angiotensin II type 1 receptor and renal allograft vascular pathology. Nephrol. Dial. Transplant. 2007; 22: 1819-1822.
17. Cheng S-M, Yang S-P, Ho L-J, Tsao T-P, Chang D-M, Lai J-H,. Irbesartan inhibits human T-lymphocyte activation through downregulation of activator protein-1. Br. J. Pharmacol. 2004; 142: 933-942.
18. Reinsmoen NL, Lai C-H, Heidecke H, et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010; 90: 1473-1477.
19. Tait BD, Süsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19-47.
20. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am. J. Transplant. 2014; 14: 272-283.
21. In JW, Park H, Rho EY, et al. Angiotensin type 1 receptor antibodies associated with antibody-mediated rejection in patients without preformed HLA-donor. Transplant. Proc. 2014; 46: 3371-3374. Elsevier Inc.
22. Wei F, Jia XJ, Yu SQ, et al. Candesartan versus imidapril in hypertension: A randomised study to assess effects of anti-AT1 receptor autoantibodies. Heart 2011; 97: 479-484.
23. Dragun D, Catar R, Philippe A,. Non-HLA antibodies in solid organ transplantation. Curr. Opin. Organ Transplant. 2013; 18: 430-435.